Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jun 19;11(3):584-90.
doi: 10.5114/aoms.2015.52362.

The beneficial effects of adjunctive recombinant human interleukin-2 for multidrug resistant tuberculosis

Hong Shen  1 , Rui Min  2 , Qi Tan  2 , Weiping Xie  2 , Hong Wang  2 , Hongqiu Pan  3 , Li Zhang  4 , Hongtao Xu  5 , Xia Zhang  6 , Jianzhong Dai  7
Affiliations

The beneficial effects of adjunctive recombinant human interleukin-2 for multidrug resistant tuberculosis

Hong Shen et al. Arch Med Sci. .

Abstract

Introduction: Multidrug-resistant tuberculosis (MDR-TB) is a hard-to-treat disease with a poor outcome of chemotherapy. In the present study, the efficacy and safety of recombinant human interleukin-2 (rhIL-2) were investigated in patients with MDR-TB.

Material and methods: Fifty culture-confirmed patients with MDR-TB were included. Twenty-five patients were randomly assigned to the trial group (injection of 500 000 IU of rhIL-2 once every other day at the first, third, fifth and seventh months in addition to standard multidrug therapy) and another 25 patients to the control group with standard multidrug therapy. All patients were monitored clinically, and T-cell subsets were analyzed by flow cytometry.

Results: The rates of sputum negative conversion and X-ray resolution in the trial group were higher than those of the control, and the improvements were significant by completion of treatment. In addition, CD4(+)CD25(+) T cells in the controls rose gradually during treatment. The levels at the end of the seventh month were significantly higher than before, which were also significantly different when compared with those from the trial group at the same time. However, there were no such changes associated with treatment in the trial group. No significant differences appeared in other T cell subsets.

Conclusions: Exogenous IL-2 in the present regimen improves immunity status. Adjunctive immunotherapy with a long period of rhIL-2 is a promising treatment modality for MDR-TB.

Keywords: CD4+CD25+ T cells; immunotherapy; interleukin-2; multidrug-resistant tuberculosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Clinical outcomes in control and rhIL-2 trial group. A – Sputum smear conversion rates. B – Sputum culture conversion rates. C – Lesion absorption rates *P < 0.05, significances determined by χ2 test. MDR-TB – multidrug-resistant tuberculosis, IL-2 – interleukin-2.
Figure 2
Figure 2
Quantities of CD4+CD25+ T cells in different groups before and after treatment *P < 0.05, Significances determined by t test. MDR-TB – multidrug-resistant tuberculosis, IL-2 – interleukin-2.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response; Geneva, Switzerland: WHO; 2010. http://www.who.int/tb/publications/2010/mdrtb2010report_executive_summar.... Accessed July 2012.m, WHO/HTM/TB/2010.3.
    1. Mercedes GJ. Immunity to TB and targets for immunotherapy. Immunotherapy. 2012;4:187–99. - PubMed
    1. Uhlin M, Andersson J, Zumla A, Maeurer M. Adjunct immunotherapies for tuberculosis. J Infect Dis. 2012;205:S325–34. - PubMed
    1. Churchyard GJ, Kaplan G, Fallows D, Wallis RS, Onyebujoh P, Rook GA. Advances in immunotherapy for tuberculosis treatment. Clin Chest Med. 2009;30:769–82. - PubMed
    1. Philips JA, Ernst JD. Tuberculosis pathogenesis and immunity. Ann Rev Pathol Mech Dis. 2012;7:353–84. - PubMed